Strides Pharma ScienceNSE:STAR -2.62%67 PB Ratio is 3.21 as of Jun. 27, 2026, which is 194% above its 10-year median of 1.09. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹773.22 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Strides Pharma Science ranks worse than 71.91% on this metric.
Strides Pharma Science Ltd stock PB Ratio (=3.3) is close to 10-year high of 3.43.
The historical rank and industry rank for Strides Pharma Science's PB Ratio or its related term are showing as below:
NSE:STAR'
s PB Ratio Range Over the Past 10 Years
Min: 0.49 Med: 1.09 Max: 3.43
Current: 3.22
During the past 13 years, Strides Pharma Science's highest PB Ratio was 3.43. The lowest was 0.49. And the median was 1.09.
NSE:STAR's PB Ratio is ranked worse than 71.91% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs NSE:STAR: 3.22
During the past 12 months, Strides Pharma Science's average Book Value Per Share Growth Rate was 21.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Strides Pharma Science was 41.10% per year. The lowest was -9.30% per year. And the median was 4.65% per year.
Back to Basics: PB Ratio
Strides Pharma Science (NSE:STAR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's PB Ratio distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Strides Pharma Science (NSE:STAR) has a PB Ratio of 3.21 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Strides Pharma Science and its competitors. This is 194% above median its historical median of 1.09. Over the past decade, Strides Pharma Science's PB Ratio has ranged from 0.49 to 3.43. According to the industry distribution chart, Strides Pharma Science ranks #663 out of 922 companies in the Drug Manufacturers industry, placing it in the top 71.9%.
Is Strides Pharma Science's PB Ratio too high?
Strides Pharma Science's current PB Ratio of 3.21 is 194% above median its 10-year median of 1.09. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 3.43. The Drug Manufacturers industry median PB Ratio is 1.83. Strides Pharma Science's value of 3.21 is 75.9% above this industry median. Based on the distribution chart, Strides Pharma Science ranks #663 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #663 out of 922 companies for PB Ratio. This places Strides Pharma Science in the lower half of its industry. The industry median PB Ratio is 1.83. Strides Pharma Science's value of 3.21 is 75.9% above this benchmark. Historically, Strides Pharma Science's own PB Ratio has ranged from 0.49 to 3.43 over the past decade. While the company's 10-year median is 1.09 vs. the industry median of 1.83, Strides Pharma Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current PB Ratio of 3.21 is 75.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current PB Ratio is 3.21, which is 194% above median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹773.22, compared to a current price of ₹1,082.20 — trading 40% above its estimated fair value. The current PB Ratio is 3.21, which is 194% above median its 10-year median of 1.09 and 75.9% above the Drug Manufacturers industry median of 1.83. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current PB Ratio is 3.21 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,082.20 is trading 40% above its estimated GF Value™ of ₹773.22.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
PB Ratio: 3.21 (194% above median its 10-year median of 1.09)
GF Value™: ₹773.22 vs. price of ₹1,082.20 (40% above fair value)
Industry Position: 75.9% above the Drug Manufacturers median (#663 of 922)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score
Get the complete analysis for NSE:STAR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
